Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

KDventures

0,30 SEK

+1,88 %

Mindre end 1K følgere

KDV B

NASDAQ Stockholm

Investment

Financials

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+1,88 %
-3,72 %
-16,19 %
-54,21 %
-62,90 %
-64,32 %
-82,23 %
-74,99 %
-98,97 %

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

Læs mere
Markedsværdi
196,21 mio. SEK
Aktieomsætning
990,53 t SEK
Omsætning
1,67 mio.
EBIT %
-11.617,24 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
30.4
2026

Delårsrapport Q1'26

12.5
2026

Generalforsamling '26

28.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse16.2.2026, 16.24

DNB Carnegie Access: KDventures: Approaching decisive data – Q4 review

KDventures
Selskabsmeddelelse13.2.2026, 07.00

Year-end Report - January-December 2025

KDventures
Selskabsmeddelelse12.2.2026, 14.45

KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue

KDventures

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse10.2.2026, 12.41

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer

KDventures
Pressemeddelelse6.2.2026, 07.05

Karolinska Development’s portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement

KDventures
Selskabsmeddelelse28.1.2026, 15.45

Karolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures AB

KDventures
Selskabsmeddelelse23.1.2026, 16.55

Karolinska Development AB receives additional guarantee commitments in ongoing rights issue

KDventures
Pressemeddelelse21.1.2026, 15.24

Karolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin

KDventures
Selskabsmeddelelse13.1.2026, 07.30

The subscription period in Karolinska Development AB (publ)’s rights issue begins today

KDventures
Selskabsmeddelelse9.1.2026, 10.35

Karolinska Development AB (publ) announces publication of information document in connection with upcoming rights issue

KDventures
Selskabsmeddelelse8.1.2026, 10.00

Karolinska Development’s Extraordinary General Meeting 2026

KDventures
Pressemeddelelse22.12.2025, 10.02

DNB Carnegie Access: Karolinska Development: Portfolio company in a reverse takeover transaction

KDventures
Pressemeddelelse22.12.2025, 07.17

Karolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development

KDventures
Pressemeddelelse11.12.2025, 07.28

Karolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D

KDventures
Pressemeddelelse10.12.2025, 12.05

Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia

KDventures
Pressemeddelelse10.12.2025, 08.25

DNB Carnegie Access: Karolinska Development: Positive study data from AnaCardio

KDventures
Selskabsmeddelelse10.12.2025, 07.00

Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01

KDventures
Selskabsmeddelelse2.12.2025, 09.23

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

KDventures
Pressemeddelelse1.12.2025, 10.25

DNB Carnegie Access: Karolinska Development: Aims to strengthen its balance shee

KDventures
Selskabsmeddelelse1.12.2025, 07.00

Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB

KDventures
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.